
Pfizer Inc.
NYSE•PFE
CEO: Dr. Albert Bourla D.V.M., Ph.D.
セクター: Healthcare
業種: Drug Manufacturers - General
上場日: 1972-06-01
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
連絡先情報
時価総額
$156.81B
PER (TTM)
20.2
35.6
配当利回り
6.2%
52週高値
$27.94
52週安値
$20.92
52週レンジ
順位23Top 9.4%
5.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$17.56B+0.00%
直近4四半期の推移
EPS
-$0.29+0.00%
直近4四半期の推移
フリーCF
$0.00+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Nine Months Net Income Rises Net income attributable to common shareholders reached $9.42B for nine months, increasing from $7.62B in prior year period.
Operating Cash Flow Strengthens Cash provided by operating activities totaled $6.36B for nine months, showing an increase over the $6.02B generated last year.
Biopharma Revenue Declines Moderated Biopharma total revenues were $44.06B for nine months, an operational decline of 2% compared to $44.99B previously.
Major R&D In-Licensing Charge Recorded $1.35B charge in Q3 2025 for exclusive global in-licensing agreement with 3SBio for SSGJ-707 compound.
リスク要因
COVID Product Demand Decreasing Operational revenue decline driven by lower Paxlovid demand due to reduced infection rates and narrower Comirnaty recommendations.
Patent Expiries Looming Anticipate more significant revenue impact from patent-based and regulatory exclusivity expirations between 2026 through 2030.
Legal Contingencies Uncertainty Subject to numerous contingencies including patent litigation and product liability claims; loss estimation remains complex.
Tax Rate Fluctuations Impact Effective tax rate for continuing operations was negative (6.5)% in Q3 2025 due to jurisdictional mix and tax benefits.
見通し
Cost Realignment Program Progress Multi-year cost realignment program targets $5.7B net cost savings through 2027, focusing on productivity and R&D efficiency.
Metsera Acquisition Planned Definitive agreement signed to acquire Metsera, a clinical-stage company, for $4.9B enterprise value, pending closing conditions.
Strategic R&D Focus Shift Combined former Oncology R&D divisions into a single Pfizer R&D organization to sharpen discovery and development focus.
Capital Allocation Priorities Maintained Framework centers on growing dividend, reinvesting in business, and making share repurchases after prudent balance sheet deleveraging.
同業比較
売上高 (TTM)
MRK$65.01B
PFE$62.58B
SNY$52.71B
粗利益率 (最新四半期)
MRK92.7%
GILD86.8%
AMGN81.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| MRK | $303.26B | 16.6 | 36.3% | 0.0% |
| NVO | $220.42B | 13.5 | 61.1% | 24.1% |
| AMGN | $198.80B | 25.8 | 96.7% | 60.3% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
8.6%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年4月27日
EPS:-
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月28日|提出日: 2025年11月4日|売上高: $16.65B-5.9%|EPS: $0.62-21.4%予想通りForm 10-Q - Q2 2025
会計期末: 2025年6月29日|提出日: 2025年8月5日|売上高: $14.65B+10.3%|EPS: $0.51+12042.9%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月30日|提出日: 2025年5月5日|売上高: $13.72B-7.8%|EPS: $0.52-5.2%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月27日|売上高: $63.63B+6.8%|EPS: $1.42+278.2%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月29日|提出日: 2024年11月4日|売上高: $17.70B+31.2%|EPS: $0.79-286.2%予想を上回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月5日|売上高: $13.28B+2.1%|EPS: $0.00-99.0%予想を下回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月8日|売上高: $14.88B-19.5%|EPS: $0.55-43.9%予想を上回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月22日|売上高: $59.55B-40.6%|EPS: $0.38-93.3%予想を下回る